{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:48:04Z","timestamp":1790776084221,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific and technological research projects in Henan province","award":["No. 202102310106"],"award-info":[{"award-number":["No. 202102310106"]}]},{"name":"Scientific and technological research projects in Henan province","award":["No. 202102310106"],"award-info":[{"award-number":["No. 202102310106"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>NK\/T cell lymphoma (NKTCL) represents an aggressive lymphoid malignancy characterized by dismal prognosis. Immune-checkpoint blockade has shown promising efficacy in NKTCL. However, the molecular mechanisms underlying immune evasion in NKTCL have never been explored. Here, proteomic analysis was used to identify the differentially expressed proteins between NKTCL patients and healthy individuals. We found that S100A9, an immunosuppressive molecule, was much higher in NKTCL patients both in serum and tumor stroma. Elevated level of S100A9 was associated with advanced stage, poor overall response and early recurrence. Moreover, percentage of myeloid-derived suppressor cells (MDSCs) in peripheral blood was positively correlated with levels of S100A9. Low concentration of S100A9 promoted proliferation of NKTCL cells, while did not affect cell apoptosis and cell cycles. Furthermore, programmed death ligand 1 (PD-L1) expression on NKTCL cells was up-regulated by S100A9 through activation of ERK1\/2 signaling. Inhibition of ERK1\/2 signaling significantly decreased tumor growth and PD-L1 expression induced by S100A9. In conclusion, our research firstly identified S100A9 as an immune suppressor in the tumorigenesis of NKTCL via accumulation of MDSCs and upregulation of PD-L1 expression. S100A9 may serve as a potential target to increase the efficacy of immunotherapy in NKTCL.<\/jats:p>","DOI":"10.1038\/s41598-021-90794-3","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T10:16:36Z","timestamp":1622110596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Overexpression of S100A9 in tumor stroma contribute to immune evasion of NK\/T cell lymphoma and predict poor response rate"],"prefix":"10.1038","volume":"11","author":[{"given":"Zhiyuan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"issue":"6","key":"90794_CR1","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1007\/s11899-016-0355-9","volume":"11","author":"BM Haverkos","year":"2016","unstructured":"Haverkos, B. M. et al. Extranodal NK\/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases. Curr. Hematol. Malig. Rep. 11(6), 514\u2013527 (2016).","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"25","key":"90794_CR2","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1182\/blood-2013-01-453233","volume":"121","author":"E Tse","year":"2013","unstructured":"Tse, E. & Kwong, Y. L. How I treat NK\/T-cell lymphomas. Blood 121(25), 4997\u20135005 (2013).","journal-title":"Blood"},{"issue":"9","key":"90794_CR3","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ng.3358","volume":"47","author":"L Jiang","year":"2015","unstructured":"Jiang, L. et al. Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat. Genet. 47(9), 1061\u20131066 (2015).","journal-title":"Nat. Genet."},{"issue":"7","key":"90794_CR4","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1158\/2159-8290.CD-12-0028","volume":"2","author":"GC Koo","year":"2012","unstructured":"Koo, G. C. et al. Janus kinase 3-activating mutations identified in natural killer\/T-cell lymphoma. Cancer Discov. 2(7), 591\u2013597 (2012).","journal-title":"Cancer Discov."},{"issue":"1","key":"90794_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ajh.23570","volume":"89","author":"Y Komabayashi","year":"2014","unstructured":"Komabayashi, Y. et al. Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK\/T-cell lymphoma. Am. J. Hematol. 89(1), 25\u201333 (2014).","journal-title":"Am. J. Hematol."},{"issue":"11","key":"90794_CR6","doi-asserted-by":"publisher","first-page":"e27271","DOI":"10.1371\/journal.pone.0027271","volume":"6","author":"R Ramakrishnan","year":"2011","unstructured":"Ramakrishnan, R. et al. Epstein-Barr virus BART9 miRNA modulates LMP1 levels and affects growth rate of nasal NK T cell lymphomas. PLoS ONE 6(11), e27271 (2011).","journal-title":"PLoS ONE"},{"issue":"1","key":"90794_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1053\/j.seminhematol.2013.11.007","volume":"51","author":"R Suzuki","year":"2014","unstructured":"Suzuki, R. Pathogenesis and treatment of extranodal natural killer\/T-cell lymphoma. Semin. Hematol. 51(1), 42\u201351 (2014).","journal-title":"Semin. Hematol."},{"issue":"33","key":"90794_CR8","doi-asserted-by":"publisher","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","volume":"29","author":"M Yamaguchi","year":"2011","unstructured":"Yamaguchi, M. et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J. Clin. Oncol. 29(33), 4410\u20134416 (2011).","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"90794_CR9","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1158\/1078-0432.CCR-16-0153","volume":"22","author":"X Li","year":"2016","unstructured":"Li, X. et al. DDGP versus SMILE in newly diagnosed advanced natural killer\/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China. Clin. Cancer Res. 22(21), 5223\u20135228 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"90794_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2217\/imt-2016-0022","volume":"8","author":"J Lee","year":"2016","unstructured":"Lee, J., Kefford, R. & Carlino, M. PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy 8(6), 733\u2013746 (2016).","journal-title":"Immunotherapy"},{"issue":"10066","key":"90794_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389(10066), 255\u2013265 (2017).","journal-title":"Lancet"},{"key":"90794_CR12","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","volume":"129","author":"YL Kwong","year":"2017","unstructured":"Kwong, Y. L. et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing L-asparaginase. Blood 129, 2437\u20132442 (2017).","journal-title":"Blood"},{"issue":"1","key":"90794_CR13","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13045-016-0341-7","volume":"9","author":"XW Bi","year":"2016","unstructured":"Bi, X. W. et al. PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer\/T-cell lymphoma. J. Hematol. Oncol. 9(1), 109 (2016).","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"90794_CR14","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim, S. O. et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell 30(6), 925\u2013939 (2016).","journal-title":"Cancer Cell"},{"key":"90794_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2016.1245759","volume":"2016","author":"AM Abu El-Asrar","year":"2016","unstructured":"Abu El-Asrar, A. M. et al. Myeloid-related protein-14\/MRP-14\/S100A9\/calgranulin B is associated with inflammation in proliferative diabetic retinopathy. Ocul. Immunol. Inflamm. 2016, 1\u201310 (2016).","journal-title":"Ocul. Immunol. Inflamm."},{"issue":"7","key":"90794_CR16","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.4049\/jimmunol.181.7.4666","volume":"181","author":"P Sinha","year":"2008","unstructured":"Sinha, P. et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181(7), 4666\u20134675 (2008).","journal-title":"J. Immunol."},{"issue":"3","key":"90794_CR17","doi-asserted-by":"publisher","first-page":"e34207","DOI":"10.1371\/journal.pone.0034207","volume":"7","author":"E Kallberg","year":"2012","unstructured":"Kallberg, E. et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS ONE 7(3), e34207 (2012).","journal-title":"PLoS ONE"},{"issue":"10","key":"90794_CR18","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1084\/jem.20080132","volume":"205","author":"P Cheng","year":"2008","unstructured":"Cheng, P. et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205(10), 2235\u20132249 (2008).","journal-title":"J. Exp. Med."},{"issue":"2","key":"90794_CR19","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.canlet.2015.09.005","volume":"369","author":"A De Ponti","year":"2015","unstructured":"De Ponti, A. et al. A pro-tumorigenic function of S100A8\/A9 in carcinogen-induced hepatocellular carcinoma. Cancer Lett. 369(2), 396\u2013404 (2015).","journal-title":"Cancer Lett."},{"issue":"6","key":"90794_CR20","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1189\/jlb.0607397","volume":"83","author":"S Ghavami","year":"2008","unstructured":"Ghavami, S. et al. S100A8\/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J. Leukoc. Biol. 83(6), 1484\u20131492 (2008).","journal-title":"J. Leukoc. Biol."},{"issue":"29","key":"90794_CR21","doi-asserted-by":"publisher","first-page":"28401","DOI":"10.18632\/oncotarget.4951","volume":"6","author":"WY Fang","year":"2015","unstructured":"Fang, W. Y. et al. Elevated S100A9 expression in tumor stroma functions as an early recurrence marker for early-stage oral cancer patients through increased tumor cell invasion, angiogenesis, macrophage recruitment and interleukin-6 production. Oncotarget 6(29), 28401\u201328424 (2015).","journal-title":"Oncotarget"},{"key":"90794_CR22","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1182\/blood-2016-09-738005","volume":"129","author":"M Laouedj","year":"2017","unstructured":"Laouedj, M. et al. S100A9 induces differentiation of acute myeloid leukemia cells through TLR4. Blood 129, 1980\u20131990 (2017).","journal-title":"Blood"},{"key":"90794_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00262-017-1986-y","volume":"66","author":"R Okita","year":"2017","unstructured":"Okita, R. et al. PD-L1 overexpression is partially regulated by EGFR\/HER2 signaling and associated with poor prognosis in patients with non-small-cell lung cancer. Cancer Immunol. Immunother. 66, 865\u2013876 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"90794_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","volume":"52","author":"JS O'Donnell","year":"2017","unstructured":"O\u2019Donnell, J. S., Long, G. V., Scolyer, R. A., Teng, M. W. & Smyth, M. J. Resistance to PD1\/PDL1 checkpoint inhibition. Cancer Treat. Rev. 52, 71\u201381 (2017).","journal-title":"Cancer Treat. Rev."},{"issue":"3","key":"90794_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen, J., Jiang, C. C., Jin, L. & Zhang, X. D. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol. 27(3), 409\u2013416 (2016).","journal-title":"Ann. Oncol."},{"issue":"23","key":"90794_CR26","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer, M. G. et al. PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome. J. Clin. Oncol. 34(23), 2690\u20132697 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"28","key":"90794_CR27","doi-asserted-by":"publisher","first-page":"26483","DOI":"10.18632\/oncotarget.4494","volume":"6","author":"MT Barrett","year":"2015","unstructured":"Barrett, M. T. et al. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget 6(28), 26483\u201326493 (2015).","journal-title":"Oncotarget"},{"issue":"2","key":"90794_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/cbin.10716","volume":"41","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Bladder cancer cells induce immunosuppression of T cells by supporting PD-L1 expression in tumour macrophages partially through interleukin 10. Cell Biol. Int. 41(2), 177\u2013186 (2017).","journal-title":"Cell Biol. Int."},{"issue":"6","key":"90794_CR29","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.immuni.2016.12.004","volume":"45","author":"JL Reading","year":"2016","unstructured":"Reading, J. L. & Quezada, S. A. Too much of a good thing? Chronic IFN fuels resistance to cancer immunotherapy. Immunity 45(6), 1181\u20131183 (2016).","journal-title":"Immunity"},{"key":"90794_CR30","doi-asserted-by":"publisher","first-page":"23695","DOI":"10.1038\/srep23695","volume":"6","author":"Z Zhou","year":"2016","unstructured":"Zhou, Z. et al. S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK\/T cell lymphoma patients treated with pegaspargase\/gemcitabine. Sci. Rep. 6, 23695 (2016).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90794-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T09:00:53Z","timestamp":1670058053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-90794-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["90794"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-90794-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"11 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11220"}}